Moneycontrol PRO

Buy Eris Lifesciences; target of Rs 850: Prabhudas Lilladher

Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 850 in its research report dated May 05, 2022.

May 07, 2022 / 09:54 AM IST
  • bselive
  • nselive
Todays L/H

Prabhudas Lilladher's research report on Eris Lifesciences

Eris Lifesciences (ERIS) reported muted operating profit due to higher promotional expenses from new launches. We believe benefits of operating leverage will play out, as revenue scales up from these launches. Further acquisition of Oaknet gives Eris an entry in the derma segment, currently operating at sub optimal profitability. Eris’s turnaround of Strides acquired portfolio provides comfort for similar execution. The company continues to outperform cardio metabolic market (60% of its total revenues) which expects robust growth over next 3-4 years with wide patent expiration opportunities.


Our FY23/24E EPS stands cut by 6%/3%, as we factor in Oaknet acquisition and lower margin assumption in base business. Maintain ‘BUY’ rating with TP of Rs850, valuing at 17x EV/EBITDA on FY24E.

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: May 7, 2022 09:54 am
ISO 27001 - BSI Assurance Mark